Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a late-stage clinical radiopharmaceutical company developing targeted cancer drugs based on its proprietary Phospholipid Drug Conjugate (PDC) platform. The CLRB news feed on Stock Titan aggregates company announcements, scientific presentations and regulatory updates that reflect the progress of this oncology pipeline.
Investors and researchers following Cellectar’s news can track developments around its lead asset, iopofosine I 131, including data from the CLOVER WaM Phase 2b study in Waldenstrom’s macroglobulinemia, the CLOVER‑2 pediatric high‑grade glioma program, and investigator‑initiated work in head and neck cancer. News items also cover FDA designations such as Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease and Fast Track, as well as EMA PRIME and orphan designations and feedback from the EMA’s Scientific Advice Working Party on a potential Conditional Marketing Authorization filing in Europe.
The CLRB news stream highlights updates on Auger‑ and alpha‑emitting candidates CLR 121125 (CLR 125) and CLR 121225 (CLR 225), including preclinical data in triple‑negative breast cancer and pancreatic ductal adenocarcinoma, clinical trial planning, and supply agreements for key radioisotopes like actinium‑225 and astatine‑211. Financial results, capital raises, warrant transactions, and reverse stock split actions reported in SEC‑linked press releases provide additional context on how the company funds its development plans.
By monitoring this page, users can review historical and ongoing disclosures about Cellectar’s clinical results, regulatory interactions, partnerships and financing activities, all drawn from company-issued news and related filings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported financial results for the year ended December 31, 2022, highlighting a net loss of $28.6 million, or $4.05 per share, compared to a net loss of $24.1 million, or $4.35 per share, in 2021. The company held cash and equivalents of $19.9 million, down from $35.7 million in 2021, with a net cash usage of approximately $25.2 million. R&D expenses rose to $19.2 million from $17.6 million, while G&A expenses increased to $9.5 million from $6.5 million. Notably, the company presented positive clinical data from ongoing trials and announced key leadership appointments, strengthening its commercial strategy in hematology and oncology.
On March 8, 2023, Cellectar Biosciences (NASDAQ: CLRB) announced its participation in two upcoming investor conferences. The Roth Capital Partners 35th Annual Conference will take place on March 13, 2023, featuring a fireside chat from 8:30 to 8:55 AM ET. The Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 14, 2023, with a virtual presentation from 10:00 to 10:30 AM ET. Both events will include opportunities for one-on-one meetings with investors. Cellectar's focus is on developing cancer-targeting drugs, including its lead product, iopofosine, undergoing pivotal studies for various cancers.